HEPION PHARMACEUTICALS, INC. Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
HEPION PHARMACEUTICALS, INC. (HEPA) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of $0 for the 9-month period ending 2016-03-31, per its 10-Q filed 2016-05-13.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2016-05-13
- HEPION PHARMACEUTICALS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2016-03-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2015-12-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2015-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2015-03-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2014 was $0.00.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 9 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month |
|---|---|---|---|---|
| 2016-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-13 | $0.00 derived: sum of 2 quarters · filed 2016-05-13 | $0.00 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-12 | $0.00 10-Q · filed 2016-02-12 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-12 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 | $0.00 derived: sum of 2 quarters · filed 2016-02-12 | $0.00 10-Q · filed 2016-05-13 | |
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-12 | $0.00 10-Q · filed 2016-02-12 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | $0.00 10-K · filed 2014-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |